Novartis’ rare renal disease candidate shows promise in phase II
Investigational oral treatment is being investigated in C3 glomerulopathy
Read More
Tag: Renal disease
- European life sciences coalition launched to boost investment ecosystem
- 99mtc‑maraciclatide granted fast track status for ILD imaging
- Bioxytran reports rapid viral clearance in phase 2 trial
- Thx Pharma and Biocodex sign rare disease licensing deal
- AstraZeneca bladder cancer therapy wins NICE backing
